Bevacizumab for severe HHT liver issues with high heart output
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This study looks at how well the drug Bevacizumab works and how safe it is for people with HHT who have severe liver problems that cause their heart to pump too much blood. It aims to help doctors understand if this treatment can help manage these serious symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of hereditary hemorrhagic telangiectasia (HHT).
- You have been treated with Bevacizumab for severe liver problems caused by HHT that also affected your heart's pumping ability.
- You had a heart ultrasound or right heart catheterization within the 12 months before starting Bevacizumab.
- You are being cared for in a French HHT center and are registered in the national CIROCO HHT database.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (bevacizumab and adebrelimab) plus a special procedure called TACE-HAIC to treat advanced liver cancer that cannot be surgically removed. The goal is to see if this combination is safe and effective as a first-line treatment.
This trial tests if injecting a medication called bevacizumab directly into certain hard-to-treat brain blood vessel malformations can help. It is for adults with large or complex malformations that have already bled or caused serious symptoms and cannot be removed with standard surgery or procedures.
This Phase 2 trial studies whether delivering an immunotherapy drug directly into the liver’s artery, together with bevacizumab, can shrink advanced hepatocellular carcinoma. You may be considered if prior whole-body (systemic) treatment has not worked and prior local procedures were also not tolerated or failed.
This trial tests a combination of three treatments—two immunotherapy/anti-cancer drugs (bevacizumab and atezolizumab) plus a catheter-based liver treatment (TACE-HAIC)—for people with unresectable hepatocellular carcinoma (liver cancer that cannot be surgically removed). The goal is to slow or shrink the cancer.
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (bevacizumab) given through a vein or directly into the liver artery, along with standard chemotherapy directly into the liver artery, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink or control the cancer.
This Phase 2 trial tests whether atezolizumab plus bevacizumab, given along with liver cancer treatment procedures (TACE/HAIC), can help people with advanced liver cancer that cannot be removed by surgery. It mainly looks at whether these medicines can control the cancer more effectively and safely.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.